19 February 2018 ORYZON Reports Financial Results and Corporate Update for the 4th Quarter and Year Ended December 31, 2017
5 February 2018 ORYZON Appoints Clinical Development Leader Lori A. Kunkel, M.D., as a Scientific Advisor
29 January 2018 ORYZON announces First Patient In in ORY-2001 MS Phase IIA trial SATEEN and presents new data on ORY-2001 at the third annual ACTRIMS Forum 2018 in San Diego
4 December 2017 Preclinical Efficacy Data on Sickle Cell Disease of ORY-3001, a LSD1 inhibitor from ORYZON, to be presented at ASH 2017
13 November 2017 ORYZON to present new preclinical data of ORY-2001 at the Neuroscience 2017 meeting organized by the Society for Neuroscience
7 November 2017 ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2017
31 October 2017 ORYZON receives approval from AEMPS to start SATEEN: a Phase IIA clinical trial in Multiple Sclerosis with ORY-2001